Table 2.
Immunosuppression management during the first posttransplant year.
| No rejection (n = 375) |
SR (n = 46) |
CR (n = 36) |
P value | |
|---|---|---|---|---|
| Trough tacrolimus level (mean ± SD in ng/dL) | ||||
|
| ||||
| 1 month | 10.7 ± 2.9 | 10.1 ± 2.8 | 10.9 ± 4.1 | .45 |
| 4 months | 7.6 ± 2.9 | 7.4 ± 3.7 | 7.7 ± 2.6 | .89 |
| 12 months | 7.8 ± 3.9 | 7.6 ± 3.0 | 7.0 ± 3.2 | .59 |
|
| ||||
| Mycophenolate mofetil dose (mean ± SD in mg/day) | ||||
|
| ||||
| 1 month | 1673 ± 412 | 1652 ± 420 | 1607 ± 540 | .66 |
| 4 months | 1392 ± 478 | 1378 ± 480 | 1383 ± 486 | .98 |
| 12 months | 1261 ± 476 | 1181 ± 480 | 1223 ± 468 | .61 |
|
| ||||
| % of patients on corticosteroids | ||||
|
| ||||
| 12 months | 9%** | 10%* | 55%∗,∗∗ | <.0001 |
SR: subclinical rejection, CR: clinical rejection, SD; standard deviation.
*P = .0002 for CR compared to SR group.
**P < .0001 for CR compared to No rejection group.